ProPhase Labs (NASDAQ:PRPH) Stock Crosses Below 200-Day Moving Average – Here’s Why

ProPhase Labs, Inc. (NASDAQ:PRPH)’s share price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.86 and traded as low as $0.0720. ProPhase Labs shares last traded at $0.0751, with a volume of 37,941 shares changing hands.

Analyst Ratings Changes

Separately, Wall Street Zen raised ProPhase Labs to a “hold” rating in a research note on Saturday, December 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

ProPhase Labs Trading Down 8.1%

The firm has a market cap of $452,252.20, a PE ratio of -0.02 and a beta of -0.52. The company has a debt-to-equity ratio of 0.14, a current ratio of 0.14 and a quick ratio of 0.14. The business has a 50-day moving average price of $0.15 and a two-hundred day moving average price of $1.86.

Hedge Funds Weigh In On ProPhase Labs

Several hedge funds have recently added to or reduced their stakes in the business. Susquehanna International Group LLP raised its position in ProPhase Labs by 290.1% during the third quarter. Susquehanna International Group LLP now owns 397,914 shares of the company’s stock worth $182,000 after acquiring an additional 295,899 shares during the last quarter. Accretive Wealth Partners LLC acquired a new stake in shares of ProPhase Labs in the third quarter valued at approximately $114,000. Apollon Wealth Management LLC purchased a new position in shares of ProPhase Labs during the 3rd quarter worth approximately $84,000. Finally, XTX Topco Ltd purchased a new position in shares of ProPhase Labs during the 2nd quarter worth approximately $40,000. 9.45% of the stock is currently owned by hedge funds and other institutional investors.

About ProPhase Labs

ProPhase Labs, Inc is a U.S.-based specialty health sciences company that develops, manufactures and markets a range of diagnostic and therapeutic products. The company’s operations span infectious disease testing services, over-the-counter remedies and contract manufacturing for pharmaceutical and consumer health clients. ProPhase Labs leverages both in-house production facilities and distribution networks to bring targeted solutions to market.

In its diagnostics division, ProPhase Labs offers laboratory-based testing for respiratory and infectious diseases, employing molecular and immunoassay technologies.